Samjin Pharmaceuticals Co., Ltd.

KSE 005500.KS

Samjin Pharmaceuticals Co., Ltd. Receivables for the year ending December 31, 2023: USD 0.27

Samjin Pharmaceuticals Co., Ltd. Receivables is USD 0.27 for the year ending December 31, 2023, a -100.00% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Samjin Pharmaceuticals Co., Ltd. Receivables for the year ending December 31, 2022 was USD 47.31 M, a -2.02% change year over year.
Samjin Pharmaceuticals Co., Ltd. Receivables for the year ending December 31, 2021 was USD 48.28 M, a 2.27% change year over year.
Samjin Pharmaceuticals Co., Ltd. Receivables for the year ending December 31, 2020 was USD 47.21 M, a 2.69% change year over year.
Samjin Pharmaceuticals Co., Ltd. Receivables for the year ending December 31, 2019 was USD 45.97 M, a -19.90% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

KSE: 005500.KS

Samjin Pharmaceuticals Co., Ltd.

CEO	Yong-Joo Choi
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	121 Wausan Ro
Employees	586
Sector	Healthcare
Industries Biotechnology Clinical Trials Cosmetics Dental Care Eyewear Personal Care Pharmaceuticals Vaccines

Description

Samjin Pharmaceuticals Co., Ltd. engages in the research and development of pharmaceutical products in Korea. The company's products include SA001, a clinical Phase II product for the treatment of dry eye and sjogren syndrome; SJP1803/1804, a preclinical stage product for the treatment of macular degeneration; SJP601 and SJP1602 preclinical stage products for the treatment of cancer; SPJ1604 and SPJ003 clinical phase products for the treatment of cancer and diabetes; and SJP1901, SJP1902, SJP1801, and SJP006 biological testing stage products for the treatment of cancer, fibrosis, cancer immunotherapy, alzheimer's disease, Parkinson's disease, and anti-viral disease. The company was founded in 1968 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years